Michael Burnam

Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018.

Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018.

Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018.